$PSNL

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

Personalis (PSNL) received a new $18.3M task order from the U.S. Department of Veterans Affairs, bringing its cumulative VA MVP task orders to $243.3M. The stock has seen significant gains, with a 30-day return of 42.57% and a year-to-date gain of 117.58%. Analysts estimate a fair value of $15.44 per share, suggesting the stock is overvalued at its last close of $17.08. Investors should consider risks such as delayed reimbursements and potential underperformance of large contracts.

Personalis (PSNL) stock rose 24.0% after securing a new $18.3M task order from the U.S. Department of Veterans Affairs' Million Veteran Program, bringing its total VA MVP contracts to $243.3M. The company projects $168.4M revenue and $27.7M earnings by 2029, despite ongoing losses. Tempus' pending acquisition of Personalis for $1.6B highlights its value in genomics and MRD capabilities.

Personalis Inc. (PSNL) fell 6% after Craig-Hallum downgraded it to hold from buy, citing an unlikely higher bid than its announced sale to Tempus AI (TEM). Tempus shares also dropped 7.2%.

Personalis Inc. (PSNL) stock rose 9.41% after reporting Q2 revenue of $22.4M, exceeding consensus estimates. The company agreed to be acquired by Tempus AI for $16.25 per share. Clinical volume for its NeXT Personal MRD test surged 199% year over year, with guidance for over 500% clinical revenue growth in 2026. Management will halt guidance and earnings calls as the company pivots to a merger-driven setup.

Tempus AI agreed to acquire Personalis for $1.5B in July 2026. Personalis' tech supports Moderna and Merck's mRNA cancer vaccine, which showed positive Phase 3 results in August 2026. Tempus shares rose 23.91% on the news. Personalis' revenue grew 441.6% YoY in Q2 2026. Tempus reported $382.5M in Q2 2026 revenue, up 22% YoY. The deal is expected to close late Q4 2026 or early 2027.

Personalis (PSNL) reported Q2 2026 revenue of $22.36 million, up from $17.20 million a year earlier, but net loss widened to $31.68 million. For the first half of 2026, revenue was $37.83 million year on year, while net loss rose to $61.72 million. The article also notes Tempus AI’s deal to buy the remaining stake for about $1.6 billion.

Tempus AI (NASDAQ: TEM) shares rose about 12.6% in a weekly update after a $1.5B Personalis deal. The article cites strong AI healthcare adoption, gross margin of 73.5%, revenue around $1.27B, but negative EBIT margin of -14.4%. It highlights technical support near $47 and resistance around $55-$57.

Personalis (PSNL) reported Q2 2026 revenue of $22.36M, up from $17.20M a year earlier, but net loss widened to $31.68M and basic loss per share rose to $0.30 from $0.23. For H1 2026, revenue was about $37.83M, flat, while net loss grew to $61.72M. The company reaffirmed 2026 guidance of $78.0–80.0M revenue and about $105M net loss.

Personalis (Nasdaq: PSNL) reported Q2 2026 results for the quarter ended June 30. Clinical tests rose 199% to 10,384. Clinical revenue increased 442% to $2.6 million, while total revenue grew 30% to $22.4 million. The company said it secured Medicare coverage for NeXT Personal in additional IO and neoadjuvant breast cancer indications and ended the quarter with about $212.7 million in cash.